

Mer från bolaget 2018-11-02

## Toleranzia will attend BIO-Europe 2018

**Toleranzia AB's Business Development Officer Björn Löwenadler will, together with Board Member Anders Waas, attend the BIO-Europe 2018 Partnering Conference, which will take place in Copenhagen on 5-7 November.**

*"BIO-Europe is a very important conference that enables us to present Toleranzia and at the same time establish contacts with representatives from most pharmaceutical companies with interests in autoimmunity and orphan diseases," says Björn Löwenadler.*

BIO-Europe is Europe's largest partnering conference for the global biotechnology industry. Participants from virtually all parts of the biotechnology value chain come to the conference to identify investment and collaboration opportunities and to establish strategic relationships. About 4,000 people from more than 2,100 companies are expected to attend this year's conference.

**For further information, contact:**

Charlotte Friberg – CEO

Phone: +46 763 19 98 98

E-mail: [charlotte.friberg@toleranzia.com](mailto:charlotte.friberg@toleranzia.com)

---

**Om Toleranzia AB**

Toleranzia AB (556877-2866) is a Swedish public biotechnology company listed on Spotlight Stock Market. The company has developed a proprietary tolerance technology harnessing the power of the immune system for treatment of autoimmune diseases. The technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. The company's main focus is directed towards the autoimmune neuromuscular disease myasthenia gravis (MG), which is an orphan disease with a high unmet medical need. The disease prevalence is approximately 200,000 people in the EU and the US together. The hallmark of MG is a deteriorated neuromuscular transmission of electrical impulses which leads to muscle weakness that can become very serious for the patient. For MG, Toleranzia develops the drug candidate TOL2, which has the potential to be the first long-acting or curing treatment and which targets specifically the underlying cause of the disease. Toleranzia was founded by researchers at the University of Gothenburg. The company operates at the Biotech center in Gothenburg. For additional information, please visit: [www.toleranzia.com](http://www.toleranzia.com).